Mazindol CR is under clinical development by NLS Pharmaceutics and currently in Phase II for Opium (Opioid) Addiction. According to GlobalData, Phase II drugs for Opium (Opioid) Addiction have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mazindol CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mazindol CR overview
Mazindol CR (NLS-1) is under development for the treatment of attention deficit hyperactivity disorder and opioid use disorder. It is a controlled release formulation administered through oral route. The drug candidate acts by targeting dopamine and norepinephrine reuptake.
The drug candidate was under development for sleep disorders and cognitive impairment.
NLS Pharmaceutics overview
NLS Pharmaceutics (NLS Pharma) is a drug development company that focuses on a strong scientific understanding of neurobehavioral and neurocognitive disorders and their pharmacognosy. NLS Pharma is headquartered in Stans, Switzerland.
For a complete picture of Mazindol CR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
